CATX · XBRL financial data

Perspective Therapeutics financial statements, every fiscal year

The same tables from 7 filings, lined up. Matched by XBRL tag: renamed lines keep their history.

How these numbers work

Every number comes from the company's XBRL financial data filed with the SEC, and each one links to its filing.
Lines are matched by XBRL tag, so a line renamed between filings keeps its history.
* marks a quarter worked out from the filing totals: the 10-K year minus the first three quarters, or a year-to-date total minus the earlier one. Fourth-quarter earnings per share is fourth-quarter net income over the fourth-quarter weighted shares.
0 means a filing states zero; a dash (—) means no filing states that number.
“year only” means the 10-K gives the full year but not the quarters needed to work out the fourth. A worked-out quarter of revenue, cost of revenue or operating cash flow more than twice the company's largest quarter of the two years before is shown this way too.
Gross profit is shown as the company reports it; a worked-out quarter must equal revenue less cost of revenue for that quarter, or it is a dash.
Operating income can be above gross profit when the company books other operating income between the two, shown on its own line.
Shares outstanding come from each filing's cover page, as of the date printed there.
Quarters are fiscal: Q2 FY27 is the second quarter of the company's fiscal 2027.

Income statement

Fiscal years (CATX's year ends in late December)

In thousands of dollars	FY 2021Jun 30, 2021	FY 2022Jun 30, 2022	FY 2023†Dec 31, 2022	FY 2023Dec 31, 2023	FY 2024Dec 31, 2024	FY 2025Dec 31, 2025
Cost of goods and services sold	4,932	6,179	—	—	—	—
Gross profit	5,121	4,616	0	1,434	—	—
Research and development	1,427	2,582	881	21,311	41,638	84,215
General and administrative	4,691	6,621	7,486	21,064	26,613	30,233
Total operating expenses	8,567	12,007	8,672	42,375	92,340	114,448
Operating income (loss)	(3,446)	(7,391)	(8,672)	(40,941)	(90,886)	(113,564)
Interest income	59	119	618	934	10,515	8,114
Interest expense	—	0	0	84	—	—
Income tax expense (benefit)	0	0	0	(2,651)	(2,097)	(793)
Net income (loss)	(3,387)	(7,272)	(10,760)	(46,508)	(79,279)	(103,121)
Earnings per share, basic‡ USD per share	(0.30)	(0.50)	(0.80)	(1.70)	(1.23)	(1.40)
Earnings per share, diluted USD per share	—	—	—	(1.74)	(1.23)	(1.40)
Weighted average shares, basic‡ thousands of shares	10,384	14,199	14,207	26,764	64,425	73,813
Weighted average shares, diluted thousands of shares	—	—	—	26,764	64,425	73,813

‡ Per-share figures and share counts are adjusted for the 1-for-10 stock split (June 2024); filings made before it reported them unadjusted.
† Share count changed about 2x in the period ending 2022-12-31, likely a stock split with no split ratio in the XBRL data; figures before that column are not adjusted.

Fiscal years (CATX's year ends in late December)

In thousands of dollars	FY 2021Jun 30, 2021	FY 2022Jun 30, 2022	FY 2023†Dec 31, 2022	FY 2023Dec 31, 2023	FY 2024Dec 31, 2024	FY 2025Dec 31, 2025
Cash and cash equivalents	63,828	55,890	20,993	9,238	61,580	30,629
Short-term investments	0	0	22,764	0	165,336	114,108
Accounts receivable	2,013	1,608	1,363	1,165	116	6
Inventory	980	1,396	1,409	—	—	—
Prepaid and other current assets	481	435	577	1,133	4,128	3,646
Total current assets	67,302	59,329	53,215	16,837	231,160	148,389
Property and equipment, net	1,958	1,976	1,684	5,576	57,321	76,597
Right-of-use asset	768	512	378	747	2,215	1,500
Goodwill	—	—	0	24,062	0	—
Total assets	70,416	64,439	58,091	97,891	341,101	266,972
Total current liabilities	1,801	2,266	2,676	15,664	18,230	28,679
Lease liability, non-current	524	256	116	780	1,428	1,005
Total liabilities	3,010	3,162	3,449	22,712	50,433	59,941
Accumulated deficit	(91,325)	(98,597)	(105,932)	(152,440)	(231,719)	(334,840)
Total stockholders' equity	67,406	61,277	54,642	75,179	290,668	207,031
Total liabilities and equity	70,416	64,439	58,091	97,891	341,101	266,972
Common shares outstanding (cover page)‡ thousands of shares	14,192	14,211	27,997	58,692	74,052	113,933

‡ Per-share figures and share counts are adjusted for the 1-for-10 stock split (June 2024); filings made before it reported them unadjusted.
† Share count changed about 2x in the period ending 2022-12-31, likely a stock split with no split ratio in the XBRL data; figures before that column are not adjusted.

Fiscal years (CATX's year ends in late December)

In thousands of dollars	FY 2021Jun 30, 2021	FY 2022Jun 30, 2022	FY 2023†Dec 31, 2022	FY 2023Dec 31, 2023	FY 2024Dec 31, 2024	FY 2025Dec 31, 2025
Net income (loss)	(3,387)	(7,272)	(10,760)	(46,508)	(79,279)	(103,121)
Stock-based compensation	386	1,087	983	3,738	5,387	8,966
Net cash from operating activities	(2,837)	(7,710)	(10,401)	(36,913)	(18,294)	(82,484)
Purchases of property and equipment	381	266	282	1,072	54,414	12,749
Net cash from investing activities	(410)	(284)	(28,988)	24,373	(218,931)	41,228
Proceeds from issuing common stock	—	0	0	364	275,807	—
Net cash from financing activities	64,684	56	28	785	289,385	10,305
Net change in cash	61,437	(7,938)	(39,361)	(11,755)	52,160	(30,951)

† Share count changed about 2x in the period ending 2022-12-31, likely a stock split with no split ratio in the XBRL data; figures before that column are not adjusted.

SIC 2834 and related industry codes, similar size. Each row is the latest quarter reported.

How peers are chosen

SIC 2834 and related industry codes with public float (or, where float is missing, quarterly revenue) between 0.2x and 5x the company's.
Each row is the latest quarter the company has reported, named in the Quarter column; when that filing is a 10-K, it is the fourth quarter, never the full year.
Runway shows only for companies burning cash with under $10B of public float.
* marks a quarter worked out from the filing totals: for a 10-K, the year less the first three quarters; for a 10-Q, the year-to-date total less the earlier one.
A cell reading “not reported” means the filings give no figure for that quarter alone.

Company	Cash ($K)	Revenue, quarter ($K)	Operating cash flow, quarter ($K)	Shares outstanding	Runway	Quarter
Perspective Therapeutics	48,488	not reported	(20,650)*	114.2M	11.5 quarters	Q2 FY26 10-QJun 30, 2026
Rocket Pharmaceuticals	224,507	0	(39,613)*	109.8M	7.2 quarters	Q2 FY26 10-QJun 30, 2026
Natures Sunshine Products	82,503	116,985	835*	17.6M	—	Q2 FY26 10-QJun 30, 2026
Tvardi Therapeutics	15,765	not reported	(9,228)*	13.3M	1.7 quarters	Q2 FY26 10-QJun 30, 2026
SELLAS Life Sciences Group	138,343	not reported	(7,588)*	201.9M	18.2 quarters	Q2 FY26 10-QJun 30, 2026
Precigen	16,329	54,978	(17,809)*	358.0M	2.1 quarters	Q2 FY26 10-QJun 30, 2026
Silence Therapeutics	72,054	0	1,518*	141.7M	—	Q2 FY26 10-QJun 30, 2026
Cardiff Oncology	9,197	104	(11,765)*	77.8M	2.9 quarters	Q2 FY26 10-QJun 30, 2026
Rezolute	10,615	not reported	(13,146)*	96.7M	8.2 quarters	Q4 FY26 10-KJun 30, 2026

Not investment advice. Not affiliated with the U.S. SEC.